Indian API companies to grow by 7-8% and operating profit margin to improve to 12-14% in FY2025: ICRA

Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024

Pfizer announces results of ABRYSVO for RSV in immunocompromised adults

These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV

Ashland completes second expansion of Viatel bioresorbable polymers manufacturing and R&D lab in Ireland

This project is supported by the Irish Government through IDA Ireland

Novo Nordisk's H1 sales increased by 24% in Danish kroner

For the 2024 outlook, sales growth is now expected to be 22-28% at CER

Allergan Aesthetics drives India’s potential in the global aesthetic market

The International Society of Aesthetic Plastic Surgery reported that non-surgical procedures outnumbered surgical ones globally in 2020

Merck to acquire investigational B-Cell depletion therapy from Curon Biopharmaceutical

CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases

Bio-economy is going to spearhead India’s future growth story: Dr. Jitendra Singh

AstraZeneca Pharma India achieves 31% revenue growth in Q1 FY25

The results are an outcome of the company's focus on sustainable and profitable growth and reflects all the hard work and focus teams have put in over the years

Sucralose safe to use in small doses; reveals MDRF study

Observes no adverse impact of non-nutritive sweetener (NNS) - sucralose on glycemic markers

Bayer Group posts 2Q 2024 sales up 3.1% at € 11.14 billion

Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings